finanznachrichten.de
Neutralwww.finanznachrichten.de · · DE
68583878 elicera therapeutics ab elicera therapeutics announces that the final reporting and final payment from the eic accelerator for the carma study have b 399
LymphomaKillDeadTumor
Topic context
This topic has been covered 160871 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedThe announcement is a milestone payment for an ongoing clinical trial. No direct commercial mechanism is triggered: no revenue, no supply chain, no price impact. The funding is non-dilutive but small relative to typical biotech burn rates. The sector is PHARMA_BIOTECH but the commercial signal is weak.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Elicera Therapeutics received final payment of ~EUR 130,000 from EIC Accelerator.
- Total EIC funding for CARMA study reaches ~EUR 2,380,000.
- CARMA study is a Phase I/IIa trial of CAR T-cell therapy ELC-301 for B-cell lymphoma.
- Trial conducted at Uppsala University Hospital and Karolinska University Hospital.
Related stories
adgully.com
Ht Labs Eyes Cyprus as Europes AI Innovation Gateway in Presence of Nikos Christodoulides
irishtimes.com
How Do I Avoid Becoming Frail and How Is It Different From Normal Ageing
newsweek.com
Wendys the Burger Chain That Dared to Be Different Fights for Survival
rediff.com
Mutual Funds Widen Lead Over Lic in Indian Stock Market Holdings
sundaytimes.lk